Background
Retinal vein occlusion (RVO) is the second most common cause of vision loss because
of retinal vascular disease. There are 2 types of RVO: branch retinal vein occlusion
(BRVO) and central retinal vein occlusion (CRVO). The pathogenesis of RVO is multifactorial.
The role of factor V Leiden (FVL) and prothrombin mutations was examined in patients
with CRVO and BRVO.
Methods
FVL and prothrombin were investigated by extracting DNA of 88 patients with RVO. Sixteen
of the patients were diagnosed with CRVO, 4 with hemispheric retinal vein occlusion,
and 68 with BRVO. The genotyping was performed by polymerase chain reaction–restriction fragment length polymorphism.
Results
Significant differences were found in the frequencies of the genotypes for both the
FVL (G1691A) (P < 10−3, odds ratio [OR] = 17.4, confidence interval [CI] = 6.20-59) and prothrombin (G20210A)
(P = .007, OR = 5.11, CI = 1.30-29) polymorphisms between RVO patients and healthy controls.
Additionally, the frequency of the GA genotype for the G1691A polymorphism was significantly
higher among the patients in a subset of BRVO compared with controls (P < 10−3, OR = 21.4, CI = 7.34-74.2). However, no statistically significant differences were
found in the frequencies of the prothrombin G20210A polymorphism between the BRVO
group and healthy controls (P = .09, OR = 3.13, CI = 64-19.9). The frequency of both G1691A and G20210A genotypes
among the patients of a CRVO subgroup was significantly higher compared with controls
(P < 10−3, OR = 11.4, CI = 2.94-44.2; P = .007, OR = 10.8, CI = 2.15-54.1, respectively), suggesting an association between
these polymorphisms and CRVO.
Conclusions
Large study would be required to understand completely the contribution of these markers
in the risk of all types of RVO.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Stroke and Cerebrovascular DiseasesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The 10-year incidence and risk factors of retinal vein occlusion: the Beijing eye study.Ophthalmology. 2013; 12: 803-808
- Pathogenesis and risk factors in retinal vein occlusions.Erciyes Med J. 2007; 29: 312-321
- Cardiovascular and thrombophilic risk factors for central retinal vein occlusion.Eur J Intern Med. 2002; 13: 163-169
- Managing retinal vein occlusion.BMJ. 2012; 344: 499
- Retinal-vein occlusion.N Engl J Med. 2010; 363: 2135-2144
- The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia.Ophthalmology. 2010; 117: 313-319
- The burden of disease of retinal vein occlusion: review of the literature.Eye. 2011; 25: 981-988
- Age-related eye disease.Maturitas. 2013; 75: 29-33
- Branch retinal vein occlusion.J Ayub Med Coll Abbottabad. 2008; 20: 128-132
- Treatment of branch retinal vein occlusion induced macular edema with bevacizumab.BMC Ophthalmol. 2008; 8: 18
- Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities.Curr Eye Res. 2008; 33: 111-131
- Central retinal vein occlusion: current management options.Pak J Ophthalmol. 2009; 25: 56-59
- Central retinal vein occlusion: current therapeutic approach.Bull Environ Pharmacol Life Sci. 2012; 1: 1-8
- Systemic diseases associated with various types of retinal vein occlusion.Am J Ophthalmol. 2001; 131: 61-77
- Retinal vein occlusions in patients taking warfarin.Ophthalmology. 2004; 111: 1196-1200
- Is activated factor VII associated with retinal vein occlusion?.Br J Ophthalmol. 2001; 85: 1174-1178
- The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis.Thromb Haemost. 2008; 99: 925-929
- Leiden mutations and unilateral retinal vein occlusion: a regional study of eastern part of Turkey.AÜTD. 2005; 37: 57-60
- Distribution of prothrombin G20210A, factor V Leiden, and MTHFR C677T mutations in the middle Black Sea area (Tokat) of Turkey.Turk J Med Sci. 2012; 42: 1093-1097
- Thrombophilic mutations and risk of retinal vein occlusion.Arq Bras Oftalmol. 2007; 70: 971-974
- Prevalence of factor V Leiden in patients with retinal vein occlusion.Acta Ophthalmol Scand. 1999; 77: 631-633
- Heritable thrombophilia and hypofibrinolysis. Possible causes of retinal vein occlusion.Arch Ophthalmol. 1999; 117: 43-49
- Retinal vein occlusion and inherited conditions predisposing to thrombophilia.Thromb Haemost. 1998; 80: 702-703
- Prothrombotic states in retinal artery and vein occlusions.Semin Cerebrovasc Dis Stroke. 2002; 2: 134-142
- Analysis of genetic polymorphisms related to thrombosis and other risk factors in patients with retinal vein occlusion.Blood Coagul Fibrinolysis. 1998; 9: 617-622
- The 20210A allele of the prothrombin gene is not a risk factor for retinal vein occlusion.Blood Coagul Fibrinolysis. 1998; 9: 447-448
- Thrombophilia: genetic polymorphisms and their association with retinal vascular occlusive disease.Br J Ophthalmol. 2001; 85: 883-886
- Factor V Leiden and prothrombin 20210 A mutations in patients with central and branch retinal vein occlusion.Acta Ophthalmol Scand. 1999; 77: 622-624
- Role of thrombophilic gene polymorphisms in branch retinal vein occlusion.Ophthalmology. 2005; 112: 1910-1915
- Influence of factor V Leiden on the development of neovascularisation secondary to central retinal vein occlusion.Br J Ophthalmol. 2003; 87: 305-306
- Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications.Am J Hypertens. 2002; 15: 1101-1108
- Risk factors for branch retinal vein occlusion.Am J Ophthalmol. 1993; 116: 286-296
- Risk factors for central retinal vein occlusion.Arch Ophthalmol. 1996; 114: 545-554
- Systemic considerations in bilateral central retinal vein occlusion.Optometry. 2007; 78: 402-408
- Mortality and morbidity in patients with central retinal vein occlusion.Ophthalmologica. 1992; 204: 199-203
- A longitudinal analysis of risk factors associated with central retinal vein occlusion.Ophthalmology. 2013; 120: 362-370
- Risk factors for hemiretinal vein occlusion: comparison with risk factors for central and branch retinal vein occlusion: the eye disease case-control study.Ophthalmology. 1998; 105: 765-771
- An Arab selective gradient in the distribution of factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T.J Thromb Haemost. 2005; 3: 2126-2127
- Distinct association of factor V-Leiden and prothrombin G20210A mutations with deep venous thrombosis in Tunisia and Lebanon.Am J Hematol. 2006; 81: 641-643
- Factor V-Leiden mutation: a common risk factor for venous thrombosis among Lebanese patients.Thrombosis. 2012; 2012: 380681https://doi.org/10.1155/2012/380681
Article info
Publication history
Published online: March 17, 2014
Accepted:
December 29,
2013
Received in revised form:
October 30,
2013
Received:
August 14,
2013
Footnotes
The authors declare that there are no conflicts of interest.
Identification
DOI: https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.12.048
Copyright
© 2014 National Stroke Association. Published by Elsevier Inc. All rights reserved.
